|Number of samples:||8|
|Release date:||Mar 8 2017|
|Last update date:||Jun 7 2017|
|Diseases:||Lymphocytic Choriomeningitis, Neoplasms, Lymphoma, B-Cell, Marginal Zone|
|Dataset link||Development of live-attenuated lymphocytic choriomeningitis virus vectors for potent alarmin-driven CD8+ T cell induction in tumor immunotherapy|
We implanted EG7-OVA tumor cells subcutaneously into the flank of C57BL/6 mice. On day 7, when tumors became palpable, we treated them with artLCMV-OVA or left them untreated. Tumor tissue was analyzed on d9 after treatment. Gene expression profiles of inflammation-associated genes from tumor tissue of untreated or artLCMV-OVA treated animals was determined by Nanostring technology. 2 groups (untreated vs artLCMV-OVA), n=4 mice per group.
Citations per year